relative to those without T2DM, and CV disease is the leading cause of morbidity and mortality in patients with T2DM. [1] [2] In recent clinical trials, despite the use of background evidence-based secondary prevention therapies for CV disease, individuals with T2DM and atherosclerotic cardiovascular disease (ASCVD) remain at high residual CV risk. In the sitagliptin CV outcome trial (TECOS) of patients with T2DM and established ASCVD, the incidence rate for major adverse cardiovascular events (MACE) and CV death was 3.62 and 1.67 per 100-patient years, respectively, among patients in the placebo group. 3 The risk of MACE among individuals with diabetes in the placebo arm of the PEGASUS-TIMI 54 trial studying patients with chronic, stable coronary artery disease was 11.6% over a median follow-up of 33 months. 4 These high event rates highlight the unmet medical need that exists for additional treatments to reduce the burden of CV disease in patients with T2DM and established ASCVD.
Results from 2 completed placebo-controlled CV outcome trial programs with the sodium-glucose cotransporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have shown significant reductions in MACE, with nearly identical magnitude of benefit for MACE along with other outcomes including heart failure (HF) hospitalization. [5] [6] However, a significant reduction in CV death was observed only with empagliflozin. 5 The patient populations enrolled in the completed and ongoing CV outcome trials of SGLT2 inhibitors differ with respect to the proportions with established CV disease and spectrum of baseline kidney function, which may be relevant to effects of the SGLT2 inhibitors on CV and/or renal outcomes. [5] [6] [7] Moreover, differences in certain safety end points, namely risk of amputation and fractures, were observed in the completed SGLT2 inhibitor trials. [5] [6] Ertugliflozin (MK-8835, PF-04971729) is an oral, highly selective SGLT2 inhibitor with greater than 2000-fold higher selectivity for SGLT2 compared with SGLT1. Ertugliflozin inhibits renal glucose reabsorption resulting in urinary glucose excretion and thereby reducing plasma glucose and glycated hemoglobin (HbA1c) in patients with T2DM. In a large Phase 3 development program, ertugliflozin demonstrated significant and clinically meaningful reductions in HbA1c, fasting plasma glucose, body weight, and blood pressure (BP). [8] [9] [10] [11] [12] Ertugliflozin is approved in the United States (US) and the European Union as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. [13] [14] The long-term effects of ertugliflozin on CV and renal outcomes are being assessed in the eValuation of ERTugliflozin effIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV) (ClinicalTrials.gov identifier: NCT01986881). In this article, we present the trial design, baseline characteristics, and analysis plan from the VERTIS-CV trial.
Methods

Study design
The VERTIS-CV trial is a multicenter, prospective, randomized, event-driven trial in patients with T2DM and established ASCVD intended to address two overarching objectives, one focused on CV safety (noninferiority) and the other on CV and renal efficacy (superiority). The trial was designed to satisfy the US FDA guidance on demonstration of CV safety for novel antihyperglycemic agents in the pre-approval and postapproval time periods. To demonstrate adequate CV safety to support the US regulatory approval for ertugliflozin (ie, to rule out an 80% increase in CV risk in the premarketing period), a CV meta-analysis across all Phase 2/3 studies, including CV outcome events captured in VERTIS-CV up to the time of the meta-analysis, was conducted and submitted to the US FDA. To preserve the integrity of the trial data, access to the unblinded CV meta-analysis results during the ongoing conduct of VERTIS-CV was restricted by a data access plan endorsed by the US FDA and governed by confidentiality agreements. The CV meta-analysis was prepared by a small firewalled team that included a very limited number of sponsor personnel with no direct or other involvement in the ertugliflozin program. None of the authors or individuals overseeing the VERTIS-CV trial or with any role in the operations of the trial were allowed any knowledge of the CV meta-analysis results while the study was ongoing (ie, prior to database release).
Beyond the primary objective of demonstration of adequate CV safety, VERTIS-CV also includes prespecified and alpha-protected hierarchical analyses to assess the CV and renal efficacy of ertugliflozin by testing for superiority for CV and renal outcomes as described below. The trial also includes 3 glycemic sub-studies to assess the efficacy of ertugliflozin on glycemic end points, body weight, and BP in patients receiving specific antihyperglycemic background therapies (insulin with or without metformin; sulfonylurea monotherapy; and metformin plus sulfonylurea). The analysis plan also includes an assessment of the efficacy of ertugliflozin on glycemic parameters in those patients with stage 3A (estimated glomerular filtration [eGFR] 45 to b60 mL/min per 1.73 m 2 ) chronic kidney disease. The VERTIS-CV original protocol was finalized in August 2013 and had a planned sample size of approximately 4000 patients. The objective from the original protocol was to assess the non-inferiority of ertugliflozin versus placebo on MACE (defined as time to the first event of CV death, nonfatal myocardial infarction [MI] , and nonfatal stroke) in order to meet US FDA regulatory guidance for type 2 diabetes medications. Following the publication of the EMPA-REG OUTCOME results, 5 the protocol for VERTIS-CV was amended in March 2016. The key changes were to double the sample size of the trial to approximately 8000 patients and to include efficacy objectives for superiority on CV outcomes along with an efficacy assessment of a renal composite outcome. The protocol amendment for VERTIS-CV occurred prior to the conduct of the CV meta-analysis described above.
Study population
The full details of trial eligibility criteria are listed in Appendix A. Patients were eligible if they were at least 40 years of age with T2DM (HbA1c 7.0-10.5%, inclusive), and had stable, established ASCVD involving the coronary, cerebrovascular, and/or peripheral arterial systems. Specific inclusion criteria satisfying the entry criteria of established ASCVD were patients having at least 1 of the following: (a) coronary artery disease as indicated by a history of presumed spontaneous MI OR (b) coronary artery disease as indicated by a history of coronary revascularization through either a percutaneous coronary intervention or coronary artery bypass graft OR (c) ischemic (presumed atherothrombotic) cerebrovascular disease as indicated by a history of ischemic stroke OR (d) peripheral arterial disease. The most recent qualifying ASCVD event must have occurred at least 3 months prior to screening. The key exclusion criteria were type 1 diabetes mellitus or history of ketoacidosis; patients experiencing a CV event or undergoing percutaneous coronary or peripheral artery intervention between the time of screening and randomization; patients undergoing any CV surgery within 3 months of screening; eGFR b30 mL/min per 1.73 m 2 at the screening visit; New York Heart Association Class IV HF symptoms (following protocol amendment; exclusion had been Class III-IV prior to protocol amendment).
This trial was conducted in compliance with Institutional Review Boards/Ethics Committees, the principles laid down in the last revision of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and local laws and regulations relevant to the use of new therapeutic agents. All patients provided written informed consent.
Treatment protocol, follow-up, and data collection procedures
The trial schema is shown in Figure 1 . Eligible patients were centrally randomized using an interactive voice response system in a 1:1:1 ratio to placebo, ertugliflozin 5 mg, or ertugliflozin 15 mg once daily added-on to background standard of care treatment. Randomization was based on a computer-generated schedule with randomly permuted blocks. Investigational product was administered once daily in the morning without regard to food. The initial dose of investigational product was administered in the clinic at day 1. Clinic visits occur at weeks 6, 12, 18, 26, 39, and 52 during the first year of trial participation. Following the first year, participants had clinic visits every 4 months. At each visit, interval medical history, investigational product compliance, review of concomitant medications, adverse events (AEs), serious adverse events (SAEs), and potential outcomes were assessed, along with measurement of body weight and BP. Body weight was measured in duplicate using a standardized, digital scale provided by the sponsor. Triplicate measurement of sitting BP and pulse rate were performed using an automated oscillometric device. Cases of amputation were collected on a concomitant procedure page of the Case Report Form and also identified based on a search of AEs and procedures using a Customized MedDRA Query and a thorough search of the SAE comments field. Blood and urine samples were collected at selected time points throughout the trial and analyzed in a central laboratory.
Patients were also counseled on appropriate dietary and lifestyle guidelines for T2DM, in accordance with local medical standards of care for patients with T2DM. Review of patients' self-monitoring glucose logs and hypoglycemia logs was performed at each visit. A centrally read 12-lead electrocardiogram was collected at baseline, week 18, week 52, and annually thereafter. For patients providing additional informed consent, whole blood (DNA), plasma, and serum were collected at baseline and at various time points following randomization and stored for future analysis of relevant biomarkers for diabetes, cardiovascular disease, and renal disease.
All patients in the trial, including those patients taking part in the glycemic sub-studies, were required to keep their prior anti-hyperglycemic treatment stable during the first 18 weeks to enable the assessment of the glycemic effects of ertugliflozin. Adjustments in background antihyperglycemic therapy during the initial 18 weeks of the study were permitted in patients who exceeded progressively more stringent glycemic thresholds based on a repeated, confirmed fasting plasma glucose measurement. After the initial 18 weeks, the investigator and/or treating health care provider was able to make necessary adjustments in background anti-hyperglycemic therapy regimen to achieve an appropriate HbA1c level for the patient (with the exception of prohibited concomitant medications: another SGLT2 inhibitor, rosiglitazone, or chlorpropamide). A patient experiencing clinically significant hypoglycemia, according to the investigator, at any time during the trial was permitted to have the dose of appropriate background anti-hyperglycemic agent adjusted (eg, insulin, sulfonylurea, glinide). The investigator and/or treating health care provider was also able to make any changes in the background treatment regimen to achieve appropriate targets for secondary CV disease prevention, in accordance with local guidelines and standards of care.
Patients who prematurely discontinued investigational product remained in the study to continue to provide information on clinical outcomes, except in circumstances where patients withdrew consent from further participation. A follow-up phone call was conducted 14 days after the last dose of study medication to assess for AEs, SAEs, and to collect information on potential clinical events. Vital status was attempted to be collected for all patients in the trial, except where prohibited by local laws or regulations.
Study objectives and outcomes
The primary objective of the trial is to demonstrate noninferiority of ertugliflozin versus placebo on time to first MACE, defined as CV death, nonfatal MI, or nonfatal stroke. The secondary objectives are to demonstrate superiority of ertugliflozin versus placebo on time to: (1) first event of CV death or hospitalization for HF; (2) CV death; and (3) first event of renal death, dialysis/ transplant, or doubling of serum creatinine from baseline.
In accordance with US FDA guidelines, non-inferiority will be declared if the upper limit of the 95% confidence interval for the hazard ratio (HR) for MACE excludes 1.3. If non-inferiority at the 1.3 margin is established for the primary MACE outcome, then tests of superiority on the secondary outcomes will be performed in a fixed testing sequence.
Other CV outcomes pre-specified for analysis, but not part of the formal testing sequence, are the individual components of MACE, the composite of MACE-plus (CV death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina), fatal or nonfatal MI, fatal or nonfatal stroke, hospitalization for HF, all-cause mortality, all MACE events (first + all recurrent), and all CV deaths or hospitalizations for HF (first + all recurrent). For all analyses of CV outcomes, only CV events confirmed by the CV Clinical Adjudication Committee will be included.
Statistical considerations
Primary and secondary time-to-first-event outcomes will be analyzed using a stratified Cox proportional hazards model including treatment group (pooled ertugliflozin dose groups vs placebo) as a term in the model and enrollment cohort as the stratification factor. A point estimate and 2-sided confidence interval (adjusted for multiplicity) for the HR will be calculated based on the Cox model. A non-inferiority margin of 1.3 on the HR for MACE will be utilized as per US FDA guidance. One planned interim analysis will be conducted when~76% of the primary MACE outcome and CV deaths have been confirmed. In order to control the overall Type I error rate across multiple analyses and multiple outcomes, an O'Brien-Fleming alpha spending function will be utilized, and a hierarchical testing sequence will be utilized across the primary and secondary end points in the following order: (1) MACE (non-inferiority); (2) the composite of CV death or hospitalization for HF (superiority); (3) CV death (superiority); and (4) the composite of renal death, dialysis/transplant, or doubling of serum creatinine from baseline (superiority). The primary analysis set for the noninferiority analysis of the primary outcome of MACE will be the full analysis set, which will include all patients who were randomized and who received at least 1 dose of investigational product and will include confirmed events occurring up to 365 days after the last dose of investigational product for those with premature discontinuation. For the superiority analyses of CV and renal outcomes, an intent-to-treat analysis set will be utilized, which will include all randomized patients and all confirmed events with no upper limit on the event ascertainment window.
For the primary non-inferiority analysis, it is estimated that the study will have~96% power to demonstrate noninferiority, assuming accrual of at least 939 MACE events for the final analysis and a true HR of 1.00. For the secondary analyses, it is estimated that the study will have~90% power to demonstrate superiority for the composite outcome of CV death or hospitalization for HF, assuming accrual of at least 582 composite events for the final analysis and a true HR of 0.75; and~83% power to demonstrate superiority for CV death, assuming accrual of at least 377 CV deaths for the final analysis and a true HR of 0.725. For the renal composite end point, it is estimated that the study will have~79% power to demonstrate superiority assuming accrual of at least 190 renal composite events and a true HR of 0.65. The study is event-driven and will continue until accrual of 
External committees
The CV Clinical Adjudication Committee is an independent, external committee comprising cardiologists and vascular neurologists who reviewed pre-specified events in a blinded manner (Appendix B). The following events were adjudicated by the CV Clinical Adjudication Committee: all deaths, nonfatal MI or any hospitalization for chest pain where MI needs to be ruled out, nonfatal stroke (and all events that may be a stroke including all transient ischemic attack events), hospitalization for unstable angina, hospitalization for HF, and venous thromboembolism/pulmonary embolus. Any electrocardiogram that was noted via a central core-lab read to signify a potential new MI was sent for adjudication and, if positively adjudicated, was included in the end point of nonfatal MI. The trial included 4 other external adjudication committees to review safety events of interest including fractures, pancreatitis, hepatic events, and renal events (Appendix B). An internal review committee (independent of the study team) reviewed potential events of ketoacidosis.
A fully independent 5-member external Data Monitoring Committee consisting of 2 cardiologists, 2 endocrinologists, and 1 statistician (Appendix B) reviews data from the trial on an ongoing basis and will also assess the results of the pre-specified interim analysis against the stopping rules for the trial. A group of National Retention Experts were identified to work with sites to provide updates on study milestones and discuss the importance of minimizing missing data (Appendix B).
Results
Enrollment status and baseline characteristics
The initial cohort under the original protocol was randomized from December 2013 through July 2015; following a protocol amendment, the second cohort of patients was enrolled from June 2016 through April 2017. A total of 14,607 patients were screened for the trial and 6355 (43.5%) did not meet 1 or more eligibility criteria, leaving 8252 patients randomized into the trial. The most common reason for screen failure was not meeting the HbA1c entry criterion. Of the patients randomized, 6 individuals were found to have simultaneously enrolled in more than 1 ertugliflozin study and were excluded from the analysis sets because of this GCP violation. Thus, 8246 randomized patients enrolled in 34 countries comprise the intent-to-treat analysis population used for superiority testing. A total of 8238 patients received at least 1 dose of investigational product and constitute the full analysis set for the non-inferiority analysis for MACE.
Baseline demographics and characteristics of the full analysis set are shown in Table I . Patients were on average 64.4 years of age and 11% were ≥75 years old at baseline, 30% were female, and 87.8% were white. In all, 22% of patients were enrolled in North America and 56.2% enrolled from Europe. Mean baseline low-density lipoprotein cholesterol was 89 mg/dL and mean BP was 133/77 mm Hg. Mean screening HbA1c was 8.3% with an average duration of diabetes of 12.9 years. Mean eGFR was 76.0 mL/min per 1.73 m 2 , and chronic kidney disease, defined as an eGFR b60 mL/min per 1.73 m 2 , was present in 22%. Microalbuminuria (30-300 mg/g) was present in 30.2% of participants and macroalbuminuria (N300 mg/g) in 9.2%. A history of amputation existed in 3.6% of patients.
Baseline CV disease history in the full analysis set is summarized in Table II . Nearly all patients had established ASCVD at baseline with 76.3% having coronary artery disease, 23.1% having cerebrovascular disease, and 18.8% peripheral arterial disease (not mutually exclusive). At baseline, 47.9% of patients had a prior MI and 57.3% had undergone coronary revascularization. A history of stroke was present in 21.0%, and a history of HF was present in 23.1%. Information on ejection fraction (EF) at baseline was available for 1433/1900 (75.4%) of the patients with a history of HF. Among patients with a history of HF and with EF data available, the majority had HF with preserved EF defined as the most recent EF of N40% (Table II) .
At baseline, 81.4% of patients were on a statin; 84.6% were on an anti-platelet agent; 81.4% were on a reninangiotensin-aldosterone system blocker; 69.1% on a betablocker; and 40.6% were on a diuretic, including 15.4% who were receiving a loop diuretic (Figure 2A) . Regarding anti-hyperglycemic medication at study entry, 76.3% of patients were taking metformin, 41.1% were taking a sulfonylurea, and 47.2% were taking insulin (not mutually exclusive; Figure 2B ).
Discussion
The VERTIS-CV trial has completed enrollment of over 8200 patients with T2DM and established ASCVD, including a substantial proportion of elderly patients, those with HF, and those with moderate renal impairment. Studying this population will optimize the assessment of the effect of ertugliflozin on the CV and renal outcomes specified in the trial. The trial will also provide data on the glycemic efficacy of ertugliflozin in patients receiving specific anti-hyperglycemic treatments and in patients with stage 3A chronic kidney disease. Finally, the trial will provide additional data on the safety of ertugliflozin in a population at high CV risk with regard to events of special interest such as amputations, fractures, and diabetic ketoacidosis. These data will be helpful in defining the clinical impact of ertugliflozin on CV and renal outcomes and will provide further safety data for ertugliflozin. The data presented herein are based on a May 2018 data extraction date; because VERTIS-CV is ongoing, the data presented should be considered preliminary and subject to change prior to database lock.
To put VERTIS-CV and the characteristics of the patients enrolled into appropriate clinical context, the baseline characteristics of 3 other SGLT2 inhibitor CV outcome trials/trial programs are presented in Table III . [5] [6] [7] [15] [16] [17] [18] As shown, the VERTIS-CV and EMPA-REG OUTCOME trials exclusively enrolled patients with ASCVD, whereas the CANVAS program included 34% primary prevention patients and DECLARE just under 60% primary prevention. The percentage of patients with prior HF at baseline is highest in VERTIS-CV. Outcome trials comprising a mix of primary and secondary CV risk patients can yield results suggesting heterogeneity of efficacy in these 2 populations, [18] [19] [20] perhaps related to differences in underlying risk of the population, differential efficacy of the intervention, or the play of chance.
In the completed CV outcome trials with 2 SGLT2 inhibitors, the effects on some CV outcomes (eg, MACE and HF hospitalization) were nearly identical between empagliflozin and canagliflozin. In contrast, for CV death, a significant reduction was observed with empagliflozin 5 but not with canagliflozin. 6 Even among the 66% of the population in the CANVAS trials program with established ASCVD at entry, the magnitude of the estimate of the effect of canagliflozin on CV death 18 was smaller than the effect observed with empagliflozin. This could reflect a real difference in the effect of individual members of the SGLT2 inhibitor class on CV death, the result of differences in trial design or populations studied, or simply the play of chance. The results from VERTIS-CV will provide important data on the effect of ertugliflozin ASCVD, atherosclerotic cardiovascular disease; CABG, coronary artery bypass graft; HF, heart failure; HFrEF, HF with reduced ejection fraction; HFpEF, HF with preserved ejection fraction; PCI, percutaneous coronary intervention. ⁎ Percentage based on the 1433 patients with a history of heart failure and ejection fraction data available.
on CV death in a large trial population to further enhance understanding of the effect of this class of medication on CV death and within-class heterogeneity of efficacy in patients with ASCVD. Type 2 diabetes is a major risk factor for the development of HF and in many trials of patients with T2DM and ASCVD, the incidence of HF hospitalization is similar to the incidence for the outcomes of MI and stroke. 21 Thus, there is a clear unmet medical need for agents that can improve HF outcomes in patients with T2DM, especially given the increased risk of HF observed with thiazolidinediones, saxagliptin, and alogliptin. 22 As a result of the reduction in HF hospitalization risk with empagliflozin versus placebo seen in EMPA-REG 
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Background cardiovascular (A) and anti-hyperglycemic (B) medications. CVD, cardiovascular disease; DPP4i, dipeptidyl peptidase-4 inhibitor; GLP1 RA, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor antagonist; RAAS, renin-angiotensin-aldosterone system; TZD, thiazolidinedione. OUTCOME, 5,16 the VERTIS-CV protocol was amended to double the sample size of the trial and to include prespecified superiority hypotheses that are linked to the putative mechanism of action of this class of agents; namely the risk reduction for the composite of CV death/ hospitalization for HF and CV death. The inclusion of prespecified hypothesis testing for the composite outcome of CV death/hospitalization for HF distinguishes VERTIS-CV from EMPA-REG OUTCOME and from the CANVAS trials program. The amended VERTIS-CV protocol included instructions to collect EF information to be able to characterize the type of HF of the patients enrolled.
Favorable effects of SGLT2 inhibitors on diabetic kidney disease progression have been consistently demonstrated by results of placebo-controlled trials with empagliflozin and canagliflozin. 6, 23 Inclusion of the pre-specified renal composite outcome of renal death, renal replacement therapy, or doubling of serum creatinine in the VERTIS-CV hierarchical statistical testing scheme will provide further data to assess the potential for renal protection on top of standard of care treatment, including use of ACE inhibitors or angiotensin receptor blockers.
While the mechanistic underpinnings of the CV and renal efficacy observed with empagliflozin and canagliflozin and the CV mortality benefit observed with empagliflozin remain uncertain, a number of intriguing hypotheses have been proposed. 24 The early benefits on these outcomes suggest that factors other than traditional atherothrombotic risk factors contribute to the reduction in events with empagliflozin and canagliflozin. One hypothesis hinges on the effects of SGLT2 inhibition on renal sodium handling, increasing delivery of sodium to the macula densa in the juxtaglomerular apparatus and restoring tubuloglomerular feedback, the effects of which reduce glomerular hypertension and favorably modulate the renin-angiotensin-aldosterone system and sympathetic nervous system activity. 25 A second proposed mechanism relates to the effects of the SGLT2 inhibitors to increase circulating ketones, especially betahydroxybutyrate, a particularly efficient myocardial metabolic substrate. [26] [27] Third, based on their mechanism of action in the renal tubule, SGLT2 inhibitors are diuretics via osmotic effects due to urinary glucose excretion as well as natriuretic effects. 28 Finally, SGLT2 inhibitor treatment results in increased circulating hemoglobin concentration/ hematocrit, and though initial interpretation was that this most likely reflected plasma volume contraction and hemoconcentration, 29 some evidence suggests red cell mass expansion mediated by increased erythropoietin. 30 Each of these mechanisms individually and in combination could favorably affect myocardial oxygen supply/demand balance and by such mechanism(s), reduce both HF and CV death risk. Of course, all such explanations remain speculative at this point and further investigation into each is ongoing.
Conclusions
The VERTIS-CV trial is studying the safety and efficacy of ertugliflozin in T2DM patients with established ASCVD, including older patients, those with kidney disease, and those with HF. The results from this trial should define the clinical impact of ertugliflozin in patients with T2DM and ASCVD. • Patient is on a weight-loss program and is not weight-stable.
Sources of funding
• Patient is on a weight-loss medication (eg, orlistat, phentermine/topiramate, lorcaserin) and is not weight-stable.
• Patient is on other medications associated with weight changes (eg, anti-psychotic agents) and is not weight-stable.
• Patient has undergone bariatric surgery N12 months prior to Visit 1/Screening and is not weight-stable.
• Patient has undergone bariatric surgery within 12 months of Screening visit (Visit 1).
Note: Weight-stable is defined as b5% change in body weight in the last 6 months. consecutive days or repeated courses of pharmacologic doses of corticosteroids. These medications are not to be used from the time of the start of the day 1 Visit (Visit 2) to the completion of the trial.
Note: Inhaled, nasal, and topical corticosteroids and physiological replacement doses of adrenal steroids are permitted. 
